Impact News +++ Intellia Therapeutics Aktie legt zu: FDA gewährt beschleunigtes Prüfverfahren für CRISPR-Therapie (Investing.com DE) +++ INTELLIA Aktie +5,01%

INTELLIA Aktie

>INTELLIA Aktienkurs

11.5 EUR +0.5% (TradegateBSX)

Ask: 11.5 EUR / 530 Stück

Bid: 11.44 EUR / 263 Stück

Tagesumsatz: 9452 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

INTELLIA Aktie über LYNX handeln

Intraday

1 Jahr

>INTELLIA Performance

1 Woche: +5,1%

1 Monat: +11,3%

3 Monate: +2,0%

6 Monate: -0,8%

1 Jahr: +12,1%

laufendes Jahr: +46,8%

>INTELLIA Aktie

Profil:

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing medicines built on CRISPR/Cas9 technology. Intellia Therapeutics develops both in vivo therapies, which edit genes inside the body, and ex vivo..
>Volltext..

Insiderhandel:

>INTELLIA Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>INTELLIA Peer Group

Gesundheit, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten, Autoimmunerkrankungen, Onkologie/ Krebs- Behandlung

>INTELLIA Chart & Kurs - NASDAQ

>INTELLIA News

08.09.26 - 14:31	Intellia Therapeutics Aktie legt zu: FDA gewährt beschleunigtes Prüfverfahren für CRISPR-Therapie (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

04.09.26 - 15:06	Intellia Therapeutics secures $400M loan facility (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.08.26 - 18:00	Intellia (NTLA) Q2 2026 Earnings Call Transcript (Fool)
	Lonvo-z Phase III trial met primary endpoint with 87% attack reduction versus placebo....

07.08.26 - 22:09

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)

CAMBRIDGE, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on August 1, 2026, it awarded inducement grants to eight new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment....

07.08.26 - 18:15	NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues (Zacks)
	Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results....

07.08.26 - 14:33	Intellia upgraded at Evercore ISI on nex-z hypothesis (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.08.26 - 16:00	Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
	Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 0.00% and -47.22%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?...

06.08.26 - 13:18	Intellia Therapeutics GAAP EPS of -$0.80 misses by $0.01, revenue of $7.66M misses by $5.32M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.08.26 - 13:03	Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates (GlobeNewswire EN)
	CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the second quarter ended June 30, 2026....

05.08.26 - 17:42	Intellia Therapeutics Q2 2026 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.07.26 - 14:03	Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates (GlobeNewswire EN)
	CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will host a conference call on August 6, 2026, at 8 a.m. ET to discuss its second quarter 2026 financial results and business updates....

25.07.26 - 02:01	Insiderhandel: EVP, Chief Financial Officer verkauft Aktien von Intellia Therapeutics im Wert von 91249 USD (Insiderkauf)
	Dulac, Edward J III. - Vorstand - Tag der Transaktion: 2026-07-22...

09.07.26 - 18:15	NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks)
	Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism....

07.07.26 - 01:01	Insiderhandel: VP, Chief Accounting Officer verkauft Aktien von Intellia Therapeutics im Wert von 44316 USD (Insiderkauf)
	Dube, Michael P. - Vorstand - Tag der Transaktion: 2026-07-01...

07.07.26 - 01:01	Insiderhandel: EVP, Chief Financial Officer verkauft Aktien von Intellia Therapeutics im Wert von 84186 USD (Insiderkauf)
	Dulac, Edward J III. - Vorstand - Tag der Transaktion: 2026-07-02...

06.07.26 - 22:06

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)

CAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on July 1, 2026, it awarded inducement grants to thirteen new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment....

20.06.26 - 17:48	Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026? (Fool)
	Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their financials and partnerships compare....

16.06.26 - 18:15	NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up (Zacks)
	Intellia jumps after additional phase III HAELO data showed lonvo-z cut on-demand-treated attacks by 89% and moderate-to-severe episodes by 91%....

16.06.26 - 16:00	Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength? (Zacks)
	Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term....

16.06.26 - 04:48	Top Biotech Gainers: RGNT Withdraws F-1 Filing, FDA Clears CUPR′s Maggot Therapy, MYO On Watch (RTTNews)
	Today's top gainers include Regentis, amid developments including its withdrawal of a planned U.S. listing application (Form F-1) with the SEC; Cuprina, following FDA clearance for its maggot debridement therapy; and Intellia, after reporting additional positive results for its hereditary angioedema program, among others....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Was sein wird - wird sein. - Sprichwort Indien

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram